Revolution Medicines (RVMD) presented updated Phase 1b expansion data for RMC-6236 in 2L/3L RAS-mutant pancreatic ductal adenocarcinoma that provides an additional 2.5 months of follow-up on 127 patients treated at 160-300mg daily of RMC-6236, Wedbush tells investors in a research note. At the July 23 data cutoff, median progression free survival n 2L RAS-mutant patients remained at 7.6 months, which includes KRAS G12X patients, while median PFS in 3L+ RAS-mutant patients was 4.4 months, improving from 4.2 months in the KRAS G12X subset, the firm says. Wedbush says the data further validates RMC-6236’s robust anti-tumor activity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RVMD:
- Revolution Medicines presents data from RMC-6236 Monotherapy Study
- Revolution Medicines: 1st patient dosed in RMC-6236 study for PDAC treatment
- Revolution Medicines price target raised to $60 from $54 at Barclays
- Revolution Medicines participates in a conference call with JPMorgan
- Revolution Medicines added to Analyst Focus List at JPMorgan
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%20with%20Outperform%20Recommendation%20%7C%20Nasdaq&_biz_n=0&rnd=636791&cdn_o=a&_biz_z=1743706598451)
